Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Diffuse lamellar keratitis after ReLEx® SMILE and after femtolaser-assisted LASIK surgeries

Poster Details

First Author: A.Kachanov RUSSIA

Co Author(s):    S. Nikuin   S. Bauer   B. Zimin              

Abstract Details

Purpose:

To evaluate and compare the incidence and clinical features of diffuse lamellar keratitis (DLK) after ReLEx® SMILE and after femto-laser assisted LASIK (FemtoLASIK) surgeries.

Setting:

1 - St.-Petersburg branch of Sv. Fyodorov “Eye Microsurgery Clinic”; 2 – North-Western State Medical University named after I.I. Mechnikov. St.-Petersburg, Russia.

Methods:

It was a retrospective case control study. Consecutive ReLEx® SMILE (1145 eyes) and FemtoLASIK (238 eyes) myopic surgeries were performed from January 1, 2017, to December 31, 2017 with the 500 kHz VisuMax® femtosecond laser (Carl Zeiss Meditec AG, Jena) in “fast” or “expert” modes. Some clinical features (pre-op clinical characteristics, treatment parameters, intra- and post-operative complications, including DLK incidence, severity, clinical outcome and resolution) were recorded and analyzed.

Results:

There were 8 eyes (0,70%) (6 patients) developed DLK in SMILE group and 8 eyes (3,4%) (4 patients) developed DLK with the stage 1 in FemtoLASIK group. In all cases, DLK signs were noted the next day after SMILE and FemtoLASIK surgeries and there was a statistically significant increase in the incidence of DLK after FemtoLASIK than after ReLEx® SMILE (p < 0,001). There were 1 eye (0,09%) with the stage 3, 7 eyes (0,61%) with the stage 1 (among them 1 eyes with debris) in SMILE group.

Conclusions:

DLK is a very rare complication after ReLEx® SMILE than after FemtoLASIK surgery and there was a statistically significant increase in the incidence of DLK on the SMILE eyes with the low myopia and thinner lenticule (p < 0,01).

Financial Disclosure:

None

Back to Poster listing